IBN Announces Latest Episode of The BioMedWire Podcast Featuring Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.
Quantum BioPharma (QNTM) announced the release of a new BioMedWire Podcast episode featuring Executive Co-Chair Anthony Durkacz, distributed by third-party firm IBN. Durkacz reiterated the company's focus on its lead multiple sclerosis candidate, Lucid-MS, noting that an IND has been filed for a Phase 2 trial in MS patients, which will be the first time the drug is tested in humans with the disease.
Key figures
- Royalty cap usd
- 250000000
- Royalty rate initial
- 7%
- Royalty rate post cap
- 3%
- Unbuzzd ownership pct
- 19.84
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.